CINECA IRIS Institutional Research Information System

OLIVA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.285
EU - Europa 936
AS - Asia 720
OC - Oceania 48
SA - Sud America 36
AF - Africa 25
Totale 3.050
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.245
IT - Italia 332
CN - Cina 325
DE - Germania 173
JP - Giappone 134
GB - Regno Unito 107
FR - Francia 57
IN - India 54
AU - Australia 39
VN - Vietnam 38
KR - Corea 36
NL - Olanda 35
CA - Canada 32
ES - Italia 30
RU - Federazione Russa 24
PL - Polonia 23
CH - Svizzera 22
CZ - Repubblica Ceca 21
SA - Arabia Saudita 20
BE - Belgio 19
DK - Danimarca 18
ZA - Sudafrica 18
HK - Hong Kong 17
TR - Turchia 16
ID - Indonesia 15
CO - Colombia 12
BR - Brasile 11
TW - Taiwan 11
GR - Grecia 10
IE - Irlanda 9
NZ - Nuova Zelanda 9
TH - Thailandia 9
FI - Finlandia 8
PK - Pakistan 8
MX - Messico 7
SE - Svezia 7
AT - Austria 6
CL - Cile 6
KW - Kuwait 6
PT - Portogallo 6
SG - Singapore 6
SK - Slovacchia (Repubblica Slovacca) 6
AR - Argentina 4
HU - Ungheria 4
RO - Romania 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
EC - Ecuador 3
EG - Egitto 3
IL - Israele 3
JO - Giordania 3
MO - Macao, regione amministrativa speciale della Cina 3
NO - Norvegia 3
PH - Filippine 3
AL - Albania 2
AM - Armenia 2
IQ - Iraq 2
MY - Malesia 2
BG - Bulgaria 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DZ - Algeria 1
HR - Croazia 1
IR - Iran 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
Totale 3.050
Salva come PNG Salva come JPEG
Città #
Fairfield 127
Woodbridge 73
Ashburn 70
Houston 70
Torino 64
Santa Cruz 62
Seattle 61
Buffalo 58
Tokyo 52
Beijing 49
Cambridge 49
Wilmington 43
Ann Arbor 34
Wuhan 29
Dong Ket 27
Turin 26
Zhengzhou 25
Nanjing 24
Riyadh 19
Shanghai 19
Duncan 18
Hangzhou 15
Los Angeles 15
Rome 15
Loma Linda 14
New York 14
Muizenberg 13
Chicago 12
Clearwater 12
Jakarta 12
London 12
Pinerolo 12
Raritan 12
Guangzhou 10
Milan 10
Mountain View 10
Sydney 10
Changsha 9
Nürnberg 9
Rochester 9
Baotou 8
Chennai 8
Milpitas 8
San Diego 8
Taipei 8
Chengdu 7
Dublin 7
Fleming Island 7
Helsinki 7
Islamabad 7
Ontario 7
Ottawa 7
Portland 7
Saitama 7
Tianjin 7
Warsaw 7
Central 6
Central District 6
Dallas 6
Frankfurt Am Main 6
Iowa City 6
Las Vegas 6
Leawood 6
Oxford 6
Pisa 6
Seoul 6
Bengaluru 5
Boardman 5
Bratislava 5
Bremen 5
Brisbane 5
Changchun 5
Durham 5
Lake Forest 5
Lanzhou 5
Padova 5
Santiago 5
University Park 5
Vienna 5
Anzola Dell'emilia 4
Athens 4
Berlin 4
Bern 4
Bologna 4
Brussels 4
Budapest 4
Buenos Aires 4
Charlottesville 4
Clayton 4
Florence 4
Flushing 4
Fuzhou 4
Gurgaon 4
Hamilton 4
Hyderabad 4
Madrid 4
Melbourne 4
Montréal 4
Munich 4
Nashville 4
Totale 1.550
Salva come PNG Salva come JPEG
Nome #
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial, file e27ce428-2810-2581-e053-d805fe0acbaa 1.283
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma, file e27ce42a-e94a-2581-e053-d805fe0acbaa 525
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results, file e27ce427-86ab-2581-e053-d805fe0acbaa 188
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, file e27ce42f-8b46-2581-e053-d805fe0acbaa 175
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma, file e27ce42f-76fc-2581-e053-d805fe0acbaa 139
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42c-54ed-2581-e053-d805fe0acbaa 100
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma, file e27ce42f-55dd-2581-e053-d805fe0acbaa 100
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents, file e27ce430-bd95-2581-e053-d805fe0acbaa 99
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis, file e27ce42f-6e99-2581-e053-d805fe0acbaa 92
Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies, file e27ce42f-55d7-2581-e053-d805fe0acbaa 89
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial, file e27ce431-d84e-2581-e053-d805fe0acbaa 69
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives, file e27ce430-e584-2581-e053-d805fe0acbaa 61
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis, file e27ce433-b2d9-2581-e053-d805fe0acbaa 49
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino, file e27ce42e-70fd-2581-e053-d805fe0acbaa 38
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma, file e27ce434-bceb-2581-e053-d805fe0acbaa 19
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials, file e27ce432-a7ee-2581-e053-d805fe0acbaa 16
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file 489a1238-a926-41d6-a0aa-7120055380bb 15
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce435-6515-2581-e053-d805fe0acbaa 14
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives, file e27ce42f-74db-2581-e053-d805fe0acbaa 13
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file a4e97a93-3d82-4aaa-b92d-85fef843542e 12
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives, file e27ce430-e585-2581-e053-d805fe0acbaa 11
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis, file e27ce435-4480-2581-e053-d805fe0acbaa 10
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing, file e27ce431-1142-2581-e053-d805fe0acbaa 7
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis, file e27ce42f-a041-2581-e053-d805fe0acbaa 5
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate, file e27ce42f-f8a5-2581-e053-d805fe0acbaa 5
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file e27ce431-17eb-2581-e053-d805fe0acbaa 5
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma, file e27ce435-602e-2581-e053-d805fe0acbaa 4
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial, file 64fe7309-43af-4f49-aab3-bcfc7e8ba23f 3
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis, file e27ce435-47c3-2581-e053-d805fe0acbaa 2
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients., file e27ce435-7965-2581-e053-d805fe0acbaa 2
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study., file 76132f37-39f2-4e02-9047-0432fca0b928 1
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study., file bd0c03a0-25ee-4e5f-b8e8-a56c001551f7 1
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set, file e27ce431-0d6e-2581-e053-d805fe0acbaa 1
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results, file e27ce431-127a-2581-e053-d805fe0acbaa 1
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, file e27ce431-12e4-2581-e053-d805fe0acbaa 1
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial, file e27ce432-443a-2581-e053-d805fe0acbaa 1
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma, file e27ce432-d1f9-2581-e053-d805fe0acbaa 1
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved?, file e27ce432-d349-2581-e053-d805fe0acbaa 1
Totale 3.158
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.336
article - articoli 0
book - libri 0
conference - conferenze 61
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.397
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201990 0 0 0 0 0 0 0 0 0 0 53 37
2019/2020522 39 28 38 47 52 35 44 29 81 41 47 41
2020/2021768 53 51 40 55 97 77 72 89 37 57 61 79
2021/2022641 79 40 43 68 43 22 55 56 32 38 98 67
2022/2023374 20 37 80 59 22 28 28 33 16 18 29 4
2023/2024137 14 11 10 15 13 18 22 18 5 6 5 0
Totale 3.158